Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response.

ABSTRACT:

Background

In North America, both messenger RNA (mRNA) vaccines, Pfizer-BioNTech BNT162b2, and Moderna mRNA-1273, each utilizing a 2-dose regimen, have started to be administered to individuals.

Methods

We evaluated the quantitative serologic antibody response following administration of either a single dose or both doses of an mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in a cohort of 98 participants (88 healthcare workers [HCW] and 10 solid organ transplant [SOT] recipients). Antibody levels were compared across 3 immunoassays: Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics), SARS-CoV-2 TrimericS IgG (DiaSorin), and SARS-CoV-2 IgG II Quant (Abbott).

Results

Among HCW, sensitivity ranged from 100% (Roche), 99% (Abbott) and 98% (DiaSorin).

SUBMITTER: Di Meo A 

PROVIDER: S-EPMC8436397 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature